litlas
Log inCreate account

Curtis A. Hanson

Active 1990–2025

Also published as
Curtis A Hanson
136
Papers
20,091
Citations
86
h-index
130
i10-index

Citations

Citations per year for Curtis A. Hanson1983: 1 citations1986: 1 citations1991: 2 citations1992: 3 citations1993: 3 citations1994: 4 citations1995: 3 citations1996: 6 citations1997: 2 citations1998: 6 citations1999: 2 citations2000: 10 citations2001: 17 citations2002: 28 citations2003: 34 citations2004: 34 citations2005: 28 citations2006: 32 citations2007: 63 citations2008: 87 citations2009: 120 citations2010: 123 citations2011: 115 citations2012: 146 citations2013: 162 citations2014: 176 citations2015: 186 citations2016: 173 citations2017: 158 citations2018: 177 citations2019: 474 citations2020: 708 citations2021: 608 citations2022: 577 citations2023: 314 citations2024: 586 citations2025: 203 citations2026: 4 citations1984–1985: no citations, so these years are not shown1987–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,625 citing papers, 28.5% of this breakdownItaly: 566 citing papers, 9.9% of this breakdownGermany: 403 citing papers, 7.1% of this breakdownUnited Kingdom: 356 citing papers, 6.3% of this breakdownFrance: 353 citing papers, 6.2% of this breakdownSpain: 253 citing papers, 4.4% of this breakdownCanada: 189 citing papers, 3.3% of this breakdownChina: 148 citing papers, 2.6% of this breakdownNetherlands: 146 citing papers, 2.6% of this breakdownSwitzerland: 143 citing papers, 2.5% of this breakdownAustralia: 136 citing papers, 2.4% of this breakdownSweden: 117 citing papers, 2.1% of this breakdown
0%28.5%Other 22.1%

Institutions

Fields

  • Medicine87.8%
  • Biochemistry, Genetics and Molecular Biology7.2%
  • Immunology and Microbiology3.9%
  • Computer Science0.3%
  • Mathematics0.2%
  • Engineering0.1%
  • Other0.5%

Topics

  • Myeloproliferative Neoplasms: Diagnosis and Treatment13.9%
  • Acute Myeloid Leukemia Research11%
  • Chronic Lymphocytic Leukemia Research9.4%
  • Lymphoma Diagnosis and Treatment8.1%
  • Chronic Myeloid Leukemia Treatments5.2%
  • Kruppel-like factors research5.2%
  • Other47.2%

Coauthors

All papers

Open in search
  1. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Authors: Tait D. Shanafelt, Xin V. Wang, Neil E. Kay, Curtis A. Hanson, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong C. Zhang, Steven Coutré, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman - New England Journal of Medicine 2019 cited by 738

  2. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

    Authors: Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong Christine Zhang, Steven Coutré, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Neil E. Kay - Blood 2022 cited by 237

  3. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

    Authors: Paola Guglielmelli, Terra L. Lasho, Giada Rotunno, Mythri Mudireddy, Carmela Mannarelli, Maura Nicolosi, Annalisa Pacilli, Animesh Pardanani, Elisa Rumi, Vittorio Rosti, Curtis A. Hanson, Francesco Mannelli, Rhett P. Ketterling, Naseema Gangat, Alessandro Rambaldi, Francesco Passamonti, Giovanni Barosi, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi, Ayalew Tefferi - Journal of Clinical Oncology 2017 cited by 532

  4. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    Authors: Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, Geeta George, Kebede H. Begna, Susan M. Schwager, Daniel Van Dyke, Curtis A. Hanson, Wenting Wu, Animesh Pardanani, Francisco Cervantes, Francesco Passamonti, Ayalew Tefferi - Journal of Clinical Oncology 2010 cited by 1,032

  5. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

    Authors: Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson, Christy M. Finke, Emnet A Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A. Belachew, Terra L. Lasho, Rhett P. Ketterling, Curtis A. Hanson, Alessandro Rambaldi, Guido Finazzi, Jüergen Thiele, Tiziano Barbui, Animesh Pardanani, Alessandro M. Vannucchi - Blood 2014 cited by 727

  6. Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

    Authors: Ayalew Tefferi, Paola Guglielmelli, Terra L. Lasho, Giacomo Coltro, Christy M. Finke, Giuseppe Gaetano Loscocco, Benedetta Sordi, Natasha Szuber, Giada Rotunno, Annalisa Pacilli, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Alessandro M. Vannucchi - British Journal of Haematology 2020 cited by 221

  7. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

    Authors: Ayalew Tefferi, Paola Guglielmelli, Maura Nicolosi, Francesco Mannelli, Mythri Mudireddy, Niccolò Bartalucci, Christy M. Finke, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Kebede H. Begna, Naseema Gangat, Animesh Pardanani, Alessandro M. Vannucchi - Leukemia 2018 cited by 294

  8. One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

    Authors: Ayalew Tefferi, Terra L. Lasho, Thitina Jimma, Christy M. Finke, Naseema Gangat, Rakhee Vaidya, Kebede H. Begna, Aref Al‐Kali, Rhett P. Ketterling, Curtis A. Hanson, Animesh Pardanani - Mayo Clinic Proceedings 2012 cited by 249

  9. Targeted deep sequencing in polycythemia vera and essential thrombocythemia

    Authors: Ayalew Tefferi, Terra L. Lasho, Paola Guglielmelli, Christy M. Finke, Giada Rotunno, Yoseph Elala, Annalisa Pacilli, Curtis A. Hanson, Alessandro Pancrazzi, Rhett P. Ketterling, Carmela Mannarelli, Daniela Barraco, Tiziana Fanelli, Animesh Pardanani, Naseema Gangat, Alessandro M. Vannucchi - Blood Advances 2016 cited by 301

  10. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger

    Authors: Natasha Szuber, Rangit Vallapureddy, Domenico Penna, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi - American Journal of Hematology 2018 cited by 90

  11. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

    Authors: Giovanni Barosi, Ruben A. Mesa, J. Thiele, Francisco Cervantes, Peter J. Campbell, Srđan Verstovšek, Brigitte Dupriez, Ross L. Levine, Francesco Passamonti, Jason Gotlib, John T. Reilly, Alessandro M. Vannucchi, Curtis A. Hanson, Lawrence A. Solberg, Attilio Orazi, Ayalew Tefferi - Leukemia 2007 cited by 496

  12. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

    Authors: Ayalew Tefferi, Terra L. Lasho, Kebede H. Begna, Mrinal M. Patnaik, Darci Zblewski, Christy M. Finke, Rebecca R. Laborde, Emnet A Wassie, Lauren Schimek, Curtis A. Hanson, Naseema Gangat, Xiaolin Wang, Animesh Pardanani - New England Journal of Medicine 2015 cited by 322

  13. A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count

    Authors: Ayalew Tefferi, Giuseppe Gaetano Loscocco, Faiqa Farrukh, Natasha Szuber, Francesco Mannelli, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Valerio De Stefano, Alessandra Carobbio, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi - American Journal of Hematology 2023 cited by 38

  14. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients

    Authors: Maura Nicolosi, Mythri Mudireddy, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi - Leukemia 2018 cited by 81

  15. Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

    Authors: Tiziano Barbui, Jüergen Thiele, Francesco Passamonti, Elisa Rumi, Emanuela Boveri, Marco Ruggeri, Francesco Rodeghiero, Emanuele S.G. dʼAmore, Maria Luigia Randi, Irene Bertozzi, Filippo Marino, Alessandro M. Vannucchi, Elisabetta Antonioli, Valentina Carrai, Heinz Gisslinger, Veronika Buxhofer‐Ausch, Leonhard Müllauer, Alessandra Carobbio, Andrea Gianatti, Naseema Gangat, Curtis A. Hanson, Ayalew Tefferi - Journal of Clinical Oncology 2011 cited by 538

  16. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

    Authors: Andy C. Rawstron, Claudia Fazi, Andreas Agathangelidis, Neus Villamor, Rémi Letestu, Josep Nomdedéu, Carlos Palacio, Olga Stehlíková, K-A Kreuzer, Stuart Liptrot, David O’Brien, Ruth M. de Tute, Iuri Marinov, Mathieu Hauwel, Martin Špaček, Johan A. Dobber, Arnon P. Kater, Peter Gambell, Asha Soosapilla, Gerard Lozanski, Gabriele Brachtl, Ke Lin, Justin C. Boysen, Curtis A. Hanson, Jeffrey L. Jorgensen, Maryalice Stetler‐Stevenson, Constance M. Yuan, H. Elizabeth Broome, Laura Z. Rassenti, Fiona E. Craig, Julio Delgado, Carol Moreno, Francesc Bosch, A Egle, Michael Doubek, Šárka Pospı́šilová, Stephen P. Mulligan, David Westerman, Catherine Sanders, Ryan Emerson, Harlan Robins, Ilan Kirsch, Tait D. Shanafelt, Andrew R. Pettitt, Thomas J. Kipps, William G. Wierda, Florence Cymbalista, Michael Hallek, Peter Hillmen, Emili Montserrat, Paolo Ghia - Leukemia 2015 cited by 241

  17. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

    Authors: Natasha Szuber, Mythri Mudireddy, Maura Nicolosi, Domenico Penna, Rangit Vallapureddy, Terra L. Lasho, Christy M. Finke, Kebede H. Begna, Michelle A. Elliott, C. Christopher Hook, Alexandra P. Wolanskyj, Mrinal M. Patnaik, Curtis A. Hanson, Rhett P. Ketterling, Shireen Sirhan, Animesh Pardanani, Naseema Gangat, Lambert Busque, Ayalew Tefferi - Mayo Clinic Proceedings 2019 cited by 163

  18. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

    Authors: Paola Guglielmelli, Terra L. Lasho, Giada Rotunno, J Score, C Mannarelli, Alessandro Pancrazzi, Flavia Biamonte, Animesh Pardanani, Katerina Zoi, A. Reiter, Andrew Duncombe, Tiziana Fanelli, Daniela Pietra, Elisa Rumi, Christy M. Finke, Naseema Gangat, Rhett P. Ketterling, Ryan A. Knudson, Curtis A. Hanson, Alberto Bosi, Arturo Pereira, Rossella Manfredini, Francisco Cervantes, G. Barosi, M. Cazzola, Nicholas C.P. Cross, A. M. Vannucchi, Ayalew Tefferi - Leukemia 2014 cited by 308

  19. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients

    Authors: Mahnur Haider, Naseema Gangat, Terra L. Lasho, Ahmed Kamel Abou Hussein, Yoseph Elala, Curtis A. Hanson, Ayalew Tefferi - American Journal of Hematology 2016 cited by 145

  20. Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

    Authors: Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, Clive S. Zent, Thomas M. Habermann, Wei Ding, José F. Leis, Susan M. Schwager, Curtis A. Hanson, William R. Macon, Neil E. Kay, Susan L. Slager, Tait D. Shanafelt - British Journal of Haematology 2013 cited by 222

  21. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance

    Authors: Mrinal M. Patnaik, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Janice M. Hodnefield, Ryan A. Knudson, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi - American Journal of Hematology 2012 cited by 151

  22. One thousand patients with essential thrombocythemia: the Mayo Clinic experience

    Authors: Naseema Gangat, Omer Karrar, Aref Al‐Kali, Kebede H. Begna, Michelle A. Elliott, Alexandra P. Wolanskyj, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi - Blood Cancer Journal 2024 cited by 46

  23. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients

    Authors: Mrinal M. Patnaik, Raphaël Itzykson, Terra L. Lasho, Olivier Kosmider, Christy M. Finke, Curtis A. Hanson, Ryan A. Knudson, Rhett P. Ketterling, Ayalew Tefferi, Éric Solary - Leukemia 2014 cited by 282

  24. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients

    Authors: Sonia Cerquozzi, Daniela Barraco, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi - Blood Cancer Journal 2017 cited by 147